Clinical trials: Anemia in Pregnancy
Sickle Cell Disease, Chronic Kidney Disease
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia
This study will examine the use of hydroxyurea and erythropoietin for treating sickle cell disease in patients who also have kidney disease or pulmonary hypertension (high blood pressure in the lungs).
- Conditions
- Sickle Cell Disease, Chronic Kidney Disease, Pulmonary Hypertension
- Trial name
- NCT00270478
- Testing
- Erythropoietin and Hydroxyurea
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Anemia, Chronic Kidney Disease
Peginesatide for Anemia in Chronic Hemodialysis Patients
The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of peginesatide in participants with chronic kidney disease (CKD) who are on hemodialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00228449
- Testing
- peginesatide
- Where
- 14 sites in United States
- Volunteers
- 165 people
- Sponsor
- Affymax
Anemia
Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO
The investigators seek to determine whether providing inhaled nitric oxide (iNO; a vasodilator) will improve the delivery of oxygen to the brain, kidney and intestines of preterm neonates during and after the subject receives a…
- Trial name
- iNO-TRAGI (NCT02851472)
- Testing
- Inhaled Nitric Oxide
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- New York Medical College
Iron Deficiency Anaemia in Childbirth
EFFICACY OF IV VERSUS ORAL IRON IN THE TREATMENT OF IRON DEFICIENCY ANEMIA DURING PREGNANCY
This study was planned to compare outcomes of IV versus oral iron in the treatment of iron deficiency anemia during pregnancy. This study was used to investigate the efficacy of two new formulations of iron both in IV and oral…
- Trial name
- NCT07384663
- Testing
- Iron Carboxymaltose, Iron Polymaltose Complex
- Where
- Pakistan
- Volunteers
- 112 people
- Sponsor
- Dr Salaha Azam
Renal Replacement Therapy, Renal Dialysis
A Clinical Trial of IntensiVE Dialysis
This study will assess clinical outcomes of extended weekly hours of haemodialysis (>= 24 hours per week) compared with standard hours of haemodialysis (<=18 hours/week) in people with ESKD.
- Conditions
- Renal Replacement Therapy, Renal Dialysis, End Stage Kidney Disease, End Stage Renal Disease
- Trial name
- ACTIVE (NCT00649298)
- Testing
- haemodialysis
- Where
- 40 sites in Australia, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- The George Institute
Acute Renal Failure, Chronic Kidney Failure
The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
To understand how AKI (Acute Kidney Injury) leads to chronic kidney disease so therapies can be found to alter the progression of events thereby significantly impacting the long-term outcomes of children who develop AKI.
- Conditions
- Acute Renal Failure, Chronic Kidney Failure, Endothelial Dysfunction, Hemolytic-uremic Syndrome (HUS)
- Trial name
- NCT00358306
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Chronic Kidney Disease, Renal Anemia
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Roxadustat is a licensed medicine to treat anemia in adults with chronic kidney disease (CKD). Anemia is a low level of red blood cells.
- Trial name
- NCT05970172
- Testing
- Roxadustat
- Where
- 47 sites in Belgium, Croatia and 17 more
- Volunteers
- 98 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Chronic Kidney Disease
NEPHRODIAB2 Prospective Randomized Controlled Open-Labelled Trial Comparing Effect of Two Haemoglobin Levels
In type 2 diabetics, progression from chronic kidney disease to end stage renal disease may be slowed down by therapeutic interventions as angiotensin converting enzyme inhibitors use, control of high blood pressure and…
- Trial name
- NCT00279084
- Testing
- GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L., GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L
- Where
- France
- Volunteers
- 204 people
- Sponsor
- Hospices Civils de Lyon
Ovarian Neoplasms, BRCA1 Protein
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)
To determine the safety, tolerability, dose-limiting toxicity (DLT), pharmacokinetic-pharmacodynamic profile, and maximum tolerated dose (MTD) of KU-0059436 when administered orally to patients with advanced solid tumours.
- Conditions
- Ovarian Neoplasms, BRCA1 Protein, BRCA2 Protein
- Trial name
- NCT00516373
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor)
- Where
- 5 sites in Belgium, Netherlands and 2 more
- Volunteers
- 98 people
- Sponsor
- AstraZeneca
HIV, Syphilis
Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique
The general goal of the proposed study is to evaluate the cost-effectiveness of POC technologies for diagnosis of syphilis, quantitative analysis for hemoglobin and CD4 counting performed within MCH services to improve maternal…
- Conditions
- HIV, Syphilis, Anemia During Pregnancy
- Trial name
- NCT02191527
- Testing
- PIMA® for quantitative analysis of CD4-count, Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin, SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis
- Volunteers
- 1,673 people
- Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
Chronic Kidney Disease, Hemodialysis
Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.
This study investigates the relationship between Sirtuin-1 (SIRT1) levels and erythropoietin resistance in hemodialysis patients.
- Conditions
- Chronic Kidney Disease, Hemodialysis, Anemia in End Stage Renal Disease, Erythropoietin
- Trial name
- NCT06877286
- Testing
- Sirtuin-1 Level Measurement
- Where
- Turkey (Türkiye)
- Volunteers
- 391 people
- Sponsor
- Cuma Bulent Gul
Chronic Kidney Disease
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia
The objective of this study is to evaluate the efficacy and the safety when ASP1517 is intermittently administered in Erythropoiesis Stimulating Agent (ESA)-untreated non-dialysis chronic kidney disease patients with anemia.
- Trial name
- NCT02964936
- Testing
- roxadustat
- Where
- 38 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Astellas Pharma Inc
Chronic Kidney Disease, End Stage Renal Disease
TARGTEPO Treatment for Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD)
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
- Trial name
- NCT02117427
- Testing
- MDGN201 TARGTEPO
- Where
- 5 sites in Israel
- Volunteers
- 11 people
- Sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
Pre-Eclampsia, Intrauterine Growth Restriction
PEPPI Study: Identification of Women at Risk for Placental Dysfunction
The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a…
- Conditions
- Pre-Eclampsia, Intrauterine Growth Restriction, Polycystic Ovary Syndrome, Iron-deficiency
- Trial name
- NCT06115122
- Testing
- Pre-eclampsia screening program
- Where
- Finland
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Oulu University Hospital
Anemia
Paricalcitol Improves Anemia of Inflammation
Anemia of inflammation (AI) is a common comorbidity in hemodialysis patients. Paricalcitol is a selective vitamin D receptor activator with potential benefits on anti-inflammatory cytokines expression.
- Trial name
- PIERAID (NCT02876211)
- Testing
- Paricalcitol, Epoetin beta
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- Hospital Son Espases
Sickle Cell Disease, Pregnancy Related
Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease
The goal of this study is to determine if there is a positive effect of prophylactic red blood cell (RBC) transfusion of leukoreduced, ABO, Rh (D/Cc/Ee) and Kell matched blood compared to standard of care on the number of…
- Trial name
- ProTIP (NCT06979492)
- Testing
- Prophylactic Transfusion Intervention group: Transfusion, Control group
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Refractory Multiple Myeloma
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
This phase II trial studies the side effects and how well tivantinib works in treating patients with relapsed, or relapsed and refractory multiple myeloma.
- Trial name
- NCT01447914
- Testing
- Tivantinib, Diagnostic laboratory biomarker analysis, Questionnaire administration
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Anemia, Chronic Kidney Diseases
Effect of rEPO in FGF23 in ESRD Patients
Objective: To evaluate the effects of recombinant Erythropoietin (rEPO) in plasma levels of Fibroblast Growth Factor 23 (FGF23) in End-Stage Renal Disease (ESRD) patients in hemodialysis.
- Trial name
- NCT03803514
- Testing
- Recombinant EPO
- Where
- Chile
- Volunteers
- 60 people
- Sponsor
- University of Chile
Anemia, Non-Dialysis-Dependent Chronic Kidney Disease
Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease
A multicenter, randomized, open-label, active-controlled Phase 3 study for the correction of anemia and maintenance of hemoglobin (Hb) in participants with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
- Trial name
- NCT02648347
- Testing
- Vadadustat, Darbepoetin alfa
- Where
- 439 sites in United States, Argentina and 18 more
- Volunteers
- 1,751 people
- Sponsor
- Akebia Therapeutics